Mazin Thamir Abdul-Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mazin Thamir Abdul-Hasan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Karrar Mohammed Hasan Al-Gburi
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
3 shared publications - Abulfadhel Jaber Neamah Al-Shaibani
Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
2 shared publications - Ali N. Wannas
Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
2 shared publications - Inas F. Abdulrazzaq
Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
2 shared publications - Krar Kadhim Mohammed Jawad
Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
2 shared publications - Yasmien Abdul Hadi Salal
Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
2 shared publications
Latest Publications
- Open Access
- 23 December 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
PREPARATION AND CHARACTERIZATION OF SOLID DISPERSION LOADED WITH SELEXIPAG AS MODEL DRUG
Objective: The study aims to prepare solid dispersions of selexipag to enhance its aqueous solubility using two different techniques—solvent evaporation and kneading. Methods: Twenty-seven solid dispersion (SD) formulations of selexipag were prepared using two different techniques, solvent evaporation (SE) and kneading (KN). Various hydrophilic carriers were employed, including urea, polyethylene glycol 4000 (PEG 4000), polyethylene glycol 6000 (PEG 6000), poloxamer 188 (PXM 188), and poloxamer 407 (PXM 407), at drug-to-polymer ratios of 1:1, 1:3, and 1:5. The prepared formulations were evaluated for saturation solubility, drug content, percentage yield, and in vitro dissolution. Fourier transform infrared spectroscopy (FTIR) was performed to assess drug-polymer compatibility. Results: The saturation solubility was enhanced by all prepared solid dispersion formulations. The pure selexipag exhibited a solubility of 1.5 ± 0.04 µg/ml, whereas the optimized formulation (F2, PXM407:Selexipag 3:1) prepared by the solvent evaporation method showed a solubility of 25.9 ± 0.2 µg/ml, representing approximately a 17-fold increase compared to the pure drug. The optimized formulation also demonstrated a faster dissolution rate, with 88% of the drug released within 30 min. FTIR results further confirmed drug-carrier compatibility; no additional peaks were observed in any of the binary systems, indicating the absence of chemical interaction between selexipag and the polymer. Conclusion: Solid dispersion, particularly using poloxamer 407 via solvent evaporation, proved to be an effective and promising approach for enhancing the solubility, dissolution rate, and overall biopharmaceutical performance of selexipag.
- 23 December 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
Open AccessPREPARATION AND CHARACTERIZATION OF SOLID DISPERSION LOADED WITH SELEXIPAG AS MODEL DRUG
Objective: The study aims to prepare solid dispersions of selexipag to enhance its aqueous solubility using two different techniques—solvent evaporation and kneading. Methods: Twenty-seven solid dispersion (SD) formulations of selexipag were prepared using two different techniques, solvent evaporation (SE) and kneading (KN). Various hydrophilic carriers were employed, including urea, polyethylene glycol 4000 (PEG 4000), polyethylene glycol 6000 (PEG 6000), poloxamer 188 (PXM 188), and poloxamer 407 (PXM 407), at drug-to-polymer ratios of 1:1, 1:3, and 1:5. The prepared formulations were evaluated for saturation solubility, drug content, percentage yield, and in vitro dissolution. Fourier transform infrared spectroscopy (FTIR) was performed to assess drug-polymer compatibility. Results: The saturation solubility was enhanced by all prepared solid dispersion formulations. The pure selexipag exhibited a solubility of 1.5 ± 0.04 µg/ml, whereas the optimized formulation (F2, PXM407:Selexipag 3:1) prepared by the solvent evaporation method showed a solubility of 25.9 ± 0.2 µg/ml, representing approximately a 17-fold increase compared to the pure drug. The optimized formulation also demonstrated a faster dissolution rate, with 88% of the drug released within 30 min. FTIR results further confirmed drug-carrier compatibility; no additional peaks were observed in any of the binary systems, indicating the absence of chemical interaction between selexipag and the polymer. Conclusion: Solid dispersion, particularly using poloxamer 407 via solvent evaporation, proved to be an effective and promising approach for enhancing the solubility, dissolution rate, and overall biopharmaceutical performance of selexipag.
- Open Access
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 519-527
PREPARATION AND CHARACTERIZATION OF NOVEL LOXOPROFEN-LOADED SOLID LIPID NANOPARTICLES
Objective: solid lipid nanoparticles (SLNs) exhibit many beneficial characteristics in the formulation of drug delivery systems. Loxoprofen (LX) is a non-steroidal anti-inflammatory drug (NSAID). This work aims to prepare and evaluate novel LX-loaded SLNs (LX-SLNs). Methods: Experimental formulas were developed using Design-Expert 13. The Formulas were prepared via hot emulsification followed by probe ultrasonication then evaluated for their particle size, polydispersity index (PDI) and entrapment efficiency (EE%). The optimum formula was selected and lyophilized for further testing of fourier transformed-infrared spectroscopy (FTIR), powder x-ray diffraction (PXRD), and field emission scanning electronic microscopy (FE-SEM). In vitro release studies were conducted on pure LX and five formulas with varying lipid amounts and types. Results: The optimization LX-SLNs formulations was performed using Design-Expert 13, with run 13 identified as the optimal formulation. This formulation, containing glyceryl monostearate (GMS) and poloxamer 407 (PX407), showed the best overall results in terms of particle size (70±4 nm), PDI (0.02±0.001), and EE% (88.07%±0.8). The release studies demonstrated sustained release behavior, with a decrease in the release rate as the lipid amount increased. Drug-excipient compatibility was confirmed by FTIR analysis, while PXRD results showed the disappearance of the sharp peaks found in the pure materials, indicating reduced crystallinity and suggesting that the drug is either in an amorphous form or dispersed in a solid solution state. Conclusion: This study demonstrated successful encapsulation of LX in SLNs, with lipid content controlling the drug release rate. Higher lipid content demonstrated slower drug release.
- 7 September 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 519-527
Open AccessPREPARATION AND CHARACTERIZATION OF NOVEL LOXOPROFEN-LOADED SOLID LIPID NANOPARTICLES
Objective: solid lipid nanoparticles (SLNs) exhibit many beneficial characteristics in the formulation of drug delivery systems. Loxoprofen (LX) is a non-steroidal anti-inflammatory drug (NSAID). This work aims to prepare and evaluate novel LX-loaded SLNs (LX-SLNs). Methods: Experimental formulas were developed using Design-Expert 13. The Formulas were prepared via hot emulsification followed by probe ultrasonication then evaluated for their particle size, polydispersity index (PDI) and entrapment efficiency (EE%). The optimum formula was selected and lyophilized for further testing of fourier transformed-infrared spectroscopy (FTIR), powder x-ray diffraction (PXRD), and field emission scanning electronic microscopy (FE-SEM). In vitro release studies were conducted on pure LX and five formulas with varying lipid amounts and types. Results: The optimization LX-SLNs formulations was performed using Design-Expert 13, with run 13 identified as the optimal formulation. This formulation, containing glyceryl monostearate (GMS) and poloxamer 407 (PX407), showed the best overall results in terms of particle size (70±4 nm), PDI (0.02±0.001), and EE% (88.07%±0.8). The release studies demonstrated sustained release behavior, with a decrease in the release rate as the lipid amount increased. Drug-excipient compatibility was confirmed by FTIR analysis, while PXRD results showed the disappearance of the sharp peaks found in the pure materials, indicating reduced crystallinity and suggesting that the drug is either in an amorphous form or dispersed in a solid solution state. Conclusion: This study demonstrated successful encapsulation of LX in SLNs, with lipid content controlling the drug release rate. Higher lipid content demonstrated slower drug release.
- Open Access
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 439-445
FORMULATION AND CHARACTERIZATION OF ISRADIPINE SOLID DISPERSION WITH ENHANCED SOLUBILITY
Objective: This study aimed to prepare and optimize solid dispersion of isradipine, an antihypertensive drug with poor aqueous solubility using two different methods, namely, solvent evaporation and fusion. Methods: Twenty-two formulas of isradipine solid dispersion were prepared using one of the following carriers: Poloxamer 407 (PXM 407), Polyethylene Glycol 4000 (PEG 4000), Polyethylene Glycol 6000 (PEG 6000) and urea at different carrier-to-drug ratios. The produced solid dispersion formulations were evaluated for their percentage yield, drug content, solubility, and in vitro dissolution. Further investigations were performed for the selected formula; these include Differential Scanning Calorimetry (DSC), and Powder X-Ray Diffraction (PXRD) studies to evaluate the crystalline state of the drug. Besides Fourier Transformation Infrared (FTIR) spectroscopy was conducted to evaluate drug-carrier compatibility. Results: The results of this study showed that all the prepared formulas resulted in improvement in saturation solubility. Run 14 (which consists of PXM 407: isradipine in a 5:1 ratio) demonstrated a substantial increase in solubility, resulting in approximately 16 times higher solubility than the pure drug. The results of DSC and PXRD studies demonstrated complete dispersion of the drug in the carrier or amorphization of the drug. Furthermore, FTIR results indicated drug-carrier compatibility. Conclusion: From this study, it was evident that solid dispersion of isradipine in the previously mentioned carriers is an effective and efficient method to enhance its solubility. The best solubility enhancement and release profile was observed in run 14 (which combines PXM 407: isradipine in a 5:1 ratio), which was selected as the optimum formula.
- 7 January 2025
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 439-445
Open AccessFORMULATION AND CHARACTERIZATION OF ISRADIPINE SOLID DISPERSION WITH ENHANCED SOLUBILITY
Objective: This study aimed to prepare and optimize solid dispersion of isradipine, an antihypertensive drug with poor aqueous solubility using two different methods, namely, solvent evaporation and fusion. Methods: Twenty-two formulas of isradipine solid dispersion were prepared using one of the following carriers: Poloxamer 407 (PXM 407), Polyethylene Glycol 4000 (PEG 4000), Polyethylene Glycol 6000 (PEG 6000) and urea at different carrier-to-drug ratios. The produced solid dispersion formulations were evaluated for their percentage yield, drug content, solubility, and in vitro dissolution. Further investigations were performed for the selected formula; these include Differential Scanning Calorimetry (DSC), and Powder X-Ray Diffraction (PXRD) studies to evaluate the crystalline state of the drug. Besides Fourier Transformation Infrared (FTIR) spectroscopy was conducted to evaluate drug-carrier compatibility. Results: The results of this study showed that all the prepared formulas resulted in improvement in saturation solubility. Run 14 (which consists of PXM 407: isradipine in a 5:1 ratio) demonstrated a substantial increase in solubility, resulting in approximately 16 times higher solubility than the pure drug. The results of DSC and PXRD studies demonstrated complete dispersion of the drug in the carrier or amorphization of the drug. Furthermore, FTIR results indicated drug-carrier compatibility. Conclusion: From this study, it was evident that solid dispersion of isradipine in the previously mentioned carriers is an effective and efficient method to enhance its solubility. The best solubility enhancement and release profile was observed in run 14 (which combines PXM 407: isradipine in a 5:1 ratio), which was selected as the optimum formula.
- Open Access
- 7 March 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 209-214
FORMULATION, ANALYSIS AND VALIDATION OF NANOSUSPENSIONS-LOADED VORICONAZOLE TO ENHANCE SOLUBILITY
Objective: This study aimed to enhance the solubility of voriconazole (VRZ) via loading to nanosuspensions using solvent/anti-solvent technique. The optimisation of independent variables (polymer concentrations) was carried out to achieve the desired particle size and maximise the percentage of entrapment efficiency (EE %) and drug loading (DL %) using design-expert®software. Methods: Design-Expert® software, version 13, was used to design and optimise nanosuspensions-loaded VRZ using 23 factorial designs. Concentrations of polyvinylpyrrolidone, hydroxypropyl methylcellulose and poloxamers were selected as independent variables to achieve ideal particle size, polydispersity index (PDI), entrapment efficacy (EE %) and drug loading (DL %). Atomic force microscopy (AFM), differential scanning calorimetry (DSC) and saturated solubility were used to assess the lyophilized nanoparticles. The compatibility between the drug and the polymers was studied using Fourier transform infrared spectroscopy (FTIR). Results: The particle size, PDI, EE %, and DL % were in the range of 15.6–145.6 nm, 0.010-0.120, 55.9 %-91.9 %, and 6.68-36.76 %, respectively. The saturated solubility of nanosuspensions-loaded VRZ (NS-VRZ) relative to free VRZ was increased tenfold in DW and twelvefold in PBS (pH 7.4). DSC thermogram confirmed the incorporation of VRZ in the nanosuspensions. The AFM of NS-VRZ validated spherical tiny particle size with a smooth surface. There is no chemical interaction between VRZ and the polymers, according to an FTIR investigation. Conclusion: The solubility of VRZ was successfully enhanced by loading to nanosuspensions. The solvent/anti-solvent technique was proven to be cost-effective, easy to operate and suitable for the preparation of NS-VRZ using Design-Expert®software.
- 7 March 2024
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 209-214
Open AccessFORMULATION, ANALYSIS AND VALIDATION OF NANOSUSPENSIONS-LOADED VORICONAZOLE TO ENHANCE SOLUBILITY
Objective: This study aimed to enhance the solubility of voriconazole (VRZ) via loading to nanosuspensions using solvent/anti-solvent technique. The optimisation of independent variables (polymer concentrations) was carried out to achieve the desired particle size and maximise the percentage of entrapment efficiency (EE %) and drug loading (DL %) using design-expert®software. Methods: Design-Expert® software, version 13, was used to design and optimise nanosuspensions-loaded VRZ using 23 factorial designs. Concentrations of polyvinylpyrrolidone, hydroxypropyl methylcellulose and poloxamers were selected as independent variables to achieve ideal particle size, polydispersity index (PDI), entrapment efficacy (EE %) and drug loading (DL %). Atomic force microscopy (AFM), differential scanning calorimetry (DSC) and saturated solubility were used to assess the lyophilized nanoparticles. The compatibility between the drug and the polymers was studied using Fourier transform infrared spectroscopy (FTIR). Results: The particle size, PDI, EE %, and DL % were in the range of 15.6–145.6 nm, 0.010-0.120, 55.9 %-91.9 %, and 6.68-36.76 %, respectively. The saturated solubility of nanosuspensions-loaded VRZ (NS-VRZ) relative to free VRZ was increased tenfold in DW and twelvefold in PBS (pH 7.4). DSC thermogram confirmed the incorporation of VRZ in the nanosuspensions. The AFM of NS-VRZ validated spherical tiny particle size with a smooth surface. There is no chemical interaction between VRZ and the polymers, according to an FTIR investigation. Conclusion: The solubility of VRZ was successfully enhanced by loading to nanosuspensions. The solvent/anti-solvent technique was proven to be cost-effective, easy to operate and suitable for the preparation of NS-VRZ using Design-Expert®software.
- Open Access
- 7 May 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 71-79
PREPARATION AND IN VITRO EVALUATION OF SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEMS OF KETOPROFEN
Objective: The aim of this study was to formulate, evaluate and characterise nanoemulsion formulation containing a lipophilic drug, Ketoprofen. Methods: Nanoemulsion formulations composed of oil, surfactant, co-surfactants and Ketoprofen were prepared. In all formulations, the percent of surfactants, as well as oil, was varied while the amount of Ketoprofen kept constant. Solubility studies were conducted to select the oil, surfactant and cosurfactant. Phase diagrams were constructed using the aqueous phase titration method. Formulations were selected from the phase diagrams. The prepared nanoemulsions were subjected to different thermodynamic stability tests. Results: Following optimization, the F7 formula (10% oil, 3:1 surfactant to co-surfactant) was thermodynamically stable, with a droplet size of 105 nm and a zeta potential of-26.21 mV. In vitro release study showed that the drug release pattern from formulations F5, F6, F7, F8, F9 and F10 was higher than that of F1, F2, F3 and F4. Conclusion: The present work demonstrates that the nanoemulsion is a promising drug delivery system approach for the enhancement of solubility and dissolution rate of Ketoprofen.
- 7 May 2023
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 71-79
Open AccessPREPARATION AND IN VITRO EVALUATION OF SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEMS OF KETOPROFEN
Objective: The aim of this study was to formulate, evaluate and characterise nanoemulsion formulation containing a lipophilic drug, Ketoprofen. Methods: Nanoemulsion formulations composed of oil, surfactant, co-surfactants and Ketoprofen were prepared. In all formulations, the percent of surfactants, as well as oil, was varied while the amount of Ketoprofen kept constant. Solubility studies were conducted to select the oil, surfactant and cosurfactant. Phase diagrams were constructed using the aqueous phase titration method. Formulations were selected from the phase diagrams. The prepared nanoemulsions were subjected to different thermodynamic stability tests. Results: Following optimization, the F7 formula (10% oil, 3:1 surfactant to co-surfactant) was thermodynamically stable, with a droplet size of 105 nm and a zeta potential of-26.21 mV. In vitro release study showed that the drug release pattern from formulations F5, F6, F7, F8, F9 and F10 was higher than that of F1, F2, F3 and F4. Conclusion: The present work demonstrates that the nanoemulsion is a promising drug delivery system approach for the enhancement of solubility and dissolution rate of Ketoprofen.
- Open Access
- 7 November 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 127-130
A COMPARATIVE STUDY OF QUALITY CONTROL TESTING OF MEFENAMIC ACID TABLETS IN IRAQ
Objective: This research was performed to assess the quality of different marketed tablets having mefenamic acid (500 mg). The selected tablets are produced by numerous companies and presented in the Iraqi pharmaceutical marketplace. Methods: Different batches of mefenamic acid conventional tablets were exposed for several tests of quality control. These evaluation tests include hardness, weight variation, friability, disintegration time, drug content, and drug dissolution profile. The properties of these quality tests were made conferring to the specification of USP-pharmacopeia. Results: The data of this study indicate that each tablet of mefenamic acid batches conformed to the requirement of USP pharmacopeia, the hardness was (6.87-8.06 Kg/cm2), and the drug content results were (90.666-99.214%) within USP limitation. The data of disintegration time and weight uniformity were agreeable with pharmacopeia and the in vitro release assay showed that the release of each mefenamic acid marketed tablet was highest than (80 %) in 45 min, which reproducing compliance with the USP pharmacopeia's limitation. Conclusion: From this study, it was proved that all of the marketed brands of mefenamic acid tablets meet the standard character in the USP pharmacopeia for in vitro quality control tests.
- 7 November 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 127-130
Open AccessA COMPARATIVE STUDY OF QUALITY CONTROL TESTING OF MEFENAMIC ACID TABLETS IN IRAQ
Objective: This research was performed to assess the quality of different marketed tablets having mefenamic acid (500 mg). The selected tablets are produced by numerous companies and presented in the Iraqi pharmaceutical marketplace. Methods: Different batches of mefenamic acid conventional tablets were exposed for several tests of quality control. These evaluation tests include hardness, weight variation, friability, disintegration time, drug content, and drug dissolution profile. The properties of these quality tests were made conferring to the specification of USP-pharmacopeia. Results: The data of this study indicate that each tablet of mefenamic acid batches conformed to the requirement of USP pharmacopeia, the hardness was (6.87-8.06 Kg/cm2), and the drug content results were (90.666-99.214%) within USP limitation. The data of disintegration time and weight uniformity were agreeable with pharmacopeia and the in vitro release assay showed that the release of each mefenamic acid marketed tablet was highest than (80 %) in 45 min, which reproducing compliance with the USP pharmacopeia's limitation. Conclusion: From this study, it was proved that all of the marketed brands of mefenamic acid tablets meet the standard character in the USP pharmacopeia for in vitro quality control tests.
- Open Access
- 7 March 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 48-52
QUALITY EVALUATION OF BRANDS OF PROPRANOLOL HCL TABLETS AVAILABLE ON IRAQI MARKET
Objective: The purpose of this study is to evaluate the quality control of marketed tablets containing propranolol hydrochloride available on the Iraqi market and manufactured by different companies. Methods: Different batches of propranolol hydrochloride 40 mg tablets were assessed using quality control tests. Weight variation, diameter, thickness, friability, disintegration time and dissolution study were carried out in this study. Results: Based on the data obtained in this study, all brands of PPL available on the Iraqi market showed weight variation within the acceptable limit of USP. Marketed products of Becardin and Propranolol lie within the acceptable limit of hardness and Inderal was observed to be slightly higher than the normal upper range of USP. Diameter and thickness for all brands were almost the same, except the diameter of Becardin was slightly higher and friability was zero for all brands. All brands demonstrated a time of disintegration of fewer than 30 min. The tested marketed propranolol products; Inderal, Procard, Becardin and Propranolol showed cumulative drug release of 90.08%, 94.46%, 92.4% and 79.51%, respectively at the end of the first 20 min. This variation in the release profile of marketed tablets of Propranolol HCl might be attributed to the excipients present in the marketed tablets where some of these excipients may behave as a disintegrant and enhance dissolution rate while others may act as dissolution retardants. Conclusion: All marketed tablets of Propranolol HCl employed in this study were produced within the standard criteria of tablet manufacturing. Evaluation of quality control of these selected tablets showed acceptable pharmaceutical properties that lie within the limits of USP.
- 7 March 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 48-52
Open AccessQUALITY EVALUATION OF BRANDS OF PROPRANOLOL HCL TABLETS AVAILABLE ON IRAQI MARKET
Objective: The purpose of this study is to evaluate the quality control of marketed tablets containing propranolol hydrochloride available on the Iraqi market and manufactured by different companies. Methods: Different batches of propranolol hydrochloride 40 mg tablets were assessed using quality control tests. Weight variation, diameter, thickness, friability, disintegration time and dissolution study were carried out in this study. Results: Based on the data obtained in this study, all brands of PPL available on the Iraqi market showed weight variation within the acceptable limit of USP. Marketed products of Becardin and Propranolol lie within the acceptable limit of hardness and Inderal was observed to be slightly higher than the normal upper range of USP. Diameter and thickness for all brands were almost the same, except the diameter of Becardin was slightly higher and friability was zero for all brands. All brands demonstrated a time of disintegration of fewer than 30 min. The tested marketed propranolol products; Inderal, Procard, Becardin and Propranolol showed cumulative drug release of 90.08%, 94.46%, 92.4% and 79.51%, respectively at the end of the first 20 min. This variation in the release profile of marketed tablets of Propranolol HCl might be attributed to the excipients present in the marketed tablets where some of these excipients may behave as a disintegrant and enhance dissolution rate while others may act as dissolution retardants. Conclusion: All marketed tablets of Propranolol HCl employed in this study were produced within the standard criteria of tablet manufacturing. Evaluation of quality control of these selected tablets showed acceptable pharmaceutical properties that lie within the limits of USP.
- Open Access
- 7 January 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 221-225
QUALITY CONTROL TESTING OF CONVENTIONAL CLOPIDOGREL BISULFATE TABLETS MARKETED IN IRAQ
Objective: This study was employed to evaluate the quality of marketed oral tablets containing clopidogrel bisulfate. Tablets produced by various companies and commercialized in the Iraq market were used in the study. Methods: Batches of clopidogrel bisulfate conventional tablets (containing 75 mg of drug) were exposed to the quality control tests. These tests involved friability, weight variation, hardness, drug content, disintegration time, and in vitro release study; these tests were conducted depending on USP pharmacopeia. Results: The data indicate that all batches of clopidogrel bisulfate complied with the limitations of USP pharmacopeia for variation of weight, results of the hardness of tablets were 7.2-9.6 Kg/cm2. Friability value (% loss) was less than one, which was within the required limits. The time of disintegration was less than 25 min in both artificial gastric fluid (AGF) and artificial intestinal fluid (AIF). Drug content was observed between 97.1 % and 99.8 %, indicating compliance with the limits of pharmacopeia (85-115 %). An in vitro release study of batches was greater than 80 % within 25 min. Conclusion: All batches of clopidogrel bisulfate were manufactured within the criteria of tablet manufacturing. The quality control tests of tablets showed acceptable pharmaceutical properties (effectiveness and safety) that lie within the limits of USP pharmacopeia.
- 7 January 2022
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
- p. 221-225
Open AccessQUALITY CONTROL TESTING OF CONVENTIONAL CLOPIDOGREL BISULFATE TABLETS MARKETED IN IRAQ
Objective: This study was employed to evaluate the quality of marketed oral tablets containing clopidogrel bisulfate. Tablets produced by various companies and commercialized in the Iraq market were used in the study. Methods: Batches of clopidogrel bisulfate conventional tablets (containing 75 mg of drug) were exposed to the quality control tests. These tests involved friability, weight variation, hardness, drug content, disintegration time, and in vitro release study; these tests were conducted depending on USP pharmacopeia. Results: The data indicate that all batches of clopidogrel bisulfate complied with the limitations of USP pharmacopeia for variation of weight, results of the hardness of tablets were 7.2-9.6 Kg/cm2. Friability value (% loss) was less than one, which was within the required limits. The time of disintegration was less than 25 min in both artificial gastric fluid (AGF) and artificial intestinal fluid (AIF). Drug content was observed between 97.1 % and 99.8 %, indicating compliance with the limits of pharmacopeia (85-115 %). An in vitro release study of batches was greater than 80 % within 25 min. Conclusion: All batches of clopidogrel bisulfate were manufactured within the criteria of tablet manufacturing. The quality control tests of tablets showed acceptable pharmaceutical properties (effectiveness and safety) that lie within the limits of USP pharmacopeia.